Stocks and Investing
Stocks and Investing
Thu, March 17, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Reni Benjamin Maintained (ACET) at Buy with Decreased Target to $21 on, Mar 17th, 2022
Reni Benjamin of JMP Securities, Maintained "Adicet Bio, Inc." (ACET) at Buy with Decreased Target from $30 to $21 on, Mar 17th, 2022.
Reni has made no other calls on ACET in the last 4 months.
There are 3 other peers that have a rating on ACET. Out of the 3 peers that are also analyzing ACET, 0 agree with Reni's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Reni
- Asthika Goonewardene of "Truist Securities" Initiated at Strong Buy and Held Target at $30 on, Tuesday, March 8th, 2022
- Kelly Shi of "Jefferies" Initiated at Strong Buy and Held Target at $27 on, Friday, March 4th, 2022
- Michael Schmidt of "Guggenheim" Maintained at Strong Buy with Increased Target to $32 on, Monday, December 6th, 2021
Contributing Sources